Alphamab Oncology (HK:9966) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Alphamab Oncology has announced the approval of a phase I/II clinical trial for their innovative drug JSKN033, a subcutaneous co-formulation targeting HER2 and PD-L1, by the Center for Drug Evaluation in China. This trial aims to test the safety and efficacy of the drug in patients with advanced metastatic tumors. The company’s advancements in biopharmaceutical technology continue to position them as leaders in oncology drug development.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Disney (NYSE:DIS) Called Out by Trump FCC
- Ford (NYSE:F) Electric Vehicles May Have Tougher Chassis Soon
- Can Intel (NASDAQ:INTC) Come Back in 2025?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
